Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 30974270.
- Also identified by DOI 10.1016/j.wneu.2019.04.025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We here report findings on magnetic resonance imaging from a 60-year-old patient with an epithelioid glioblastoma of the corpus callosum treated with radiotherapy in combination with concomitant and adjuvant temozolomide. Neuropathology revealed a highly aggressive molecular subtype of the epithelioid glioblastoma without an isocitrate dehydrogenase and B-Raf proto-oncogene mutation or a O6-methylguanine-DNA-methyltransferase promoter hypermethylation. This subtype is typically associated with an unfavorable clinical course and poor overall survival. Unexpectedly, the first follow-up magnetic resonance imaging 10 weeks after chemoradiation completion revealed an early and almost complete treatment response.
Medical subject headings
- Brain Neoplasms
- Glioblastoma
- Isocitrate Dehydrogenase
- Proto-Oncogene Proteins B-raf